CNR2 (Cannabinoid Receptor Type-2, or CB2R) plays a highly complex, dual-natured role in tumor immunity, acting as a major immunomodulatory bridge between the endocannabinoid system and the tumor microenvironment (TME). Because CNR2 is primarily expressed on peripheral immune cells (like B cells, T cells, and macrophages) rather than the central nervous system, its activation regulates immune responses without causing the psychoactive “high” associated with CB1 receptors.
Depending on the specific type of cancer and the immune cells involved, CNR2 can either suppress or promote effective anti-tumor immune responses. 1. T-Cell Suppression: The Pro-Tumor Mechanism
In many solid tumors, CNR2 acts as an immunosuppressive brake that hampers the body’s ability to fight cancer. When cannabinoids—such as exogenous Δ9cap delta to the nineth power
-tetrahydrocannabinol (THC) or the body’s endogenous anandamide (AEA)—bind to CNR2 on T cells, they directly impair the immune response.
Leave a Reply